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Abstract
Background: Valid detection of arthritis is essential in differential diagnosis of joint pain. Indocyanin green
(ICG)-enhanced fluorescence optical imaging (FOI) is a new imaging method that visualizes inflammation in wrist
and finger joints. Objectives of this study were to compare FOI with ultrasonography (US, by gray-scale (GS) and
power Doppler (PD)) and clinical examination (CE) and to estimate the predictive power of FOI for discrimination
between inflammatory and non-inflammatory juvenile joint diseases.
Methods: FOI and GSUS/PDUS were performed in both hands of 76 patients with joint pain (53 with juvenile
idiopathic arthritis (JIA), 23 with non-inflammatory joint diseases). Inflammation was graded by a semiquantitative
score (grades 0–3) for each imaging method. Joints were defined clinically active if swollen or tender with limited
range of motion. Sensitivity and specificity of FOI in three phases dependent on ICG enhancement (P1–P3) were
analyzed with CE and GSUS/PDUS as reference.
Results: For JIA patients, FOI had an overall sensitivity of 67.3%/72.0% and a specificity of 65.0%/58.8% with GSUS/
PDUS as reference; specificity was highest in P3 (GSUS 94.3%/PDUS 91.7%). FOI was more sensitive for detecting
clinically active joints than GSUS/PDUS (75.2% vs 57.3%/32.5%). In patients with non-inflammatory joint diseases both
FOI and US showed positive (i.e., pathological) findings (25% and 14% of joints). The predictive value for discrimination
between inflammatory and non-inflammatory joint diseases was 0.79 for FOI and 0.80/0.85 for GSUS/PDUS.
Conclusions: Dependent on the phase evaluated, FOI had moderate to good agreement with CE and US. Both
imaging methods revealed limitations and should be interpreted cautiously. FOI may provide an additional diagnostic
method in pediatric rheumatology.
Trial registration: Deutsches Register Klinischer Studien DRKS00012572. Registered 31 July 2017.
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Background
Joint pain is a common complaint in children and
adolescents, about 10–20% of school children being
affected [1–3]. Distinguishing inflammatory from non-
inflammatory causes is an important diagnostic step, but
can be challenging. Juvenile idiopathic arthritis (JIA) is the
most common chronic inflammatory rheumatic disease in
childhood and requires early and adequate anti-
inflammatory treatment [4, 5] as it may lead to permanent
joint damage and functional disability [6–8]. Non-
inflammatory causes of joint pain like idiopathic pain
syndromes may require other modes of treatment in an
interdisciplinary therapeutic approach [9].
The current International League of Associations for
Rheumatology (ILAR) classification criteria of JIA and
its treatment strategies and prognosis are, among other
criteria, based on the number of inflamed joints involved
(<5 vs ≥ 5, oligoarthritis vs polyarthritis) [4, 10], and
therefore accurate detection of arthritis in any joint is
essential. However, sensitive detection by clinical exam-
ination (CE) alone can be difficult, especially in cases of
mild arthritis. Ultrasonography (US) in gray-scale (GS)
and in power Doppler mode (PD) are established im-
aging tools for both the detection of synovitis and esti-
mation of current arthritis activity; both techniques have
been shown to be more sensitive than CE [11–13]. US
allows an immediate, safe, and inexpensive evaluation
and is well suited for children. However, it is known to
have a relatively high observer dependency [14]. Mag-
netic resonance imaging (MRI) is regarded as the gold
standard for assessment of arthritis in both adults and
children [15–18]. However, discrimination between
pathological and age-related physiological changes in
children and adolescents proves to be problematic [19].
Because of further disadvantages such as high costs, long
duration of examination, and the possible need for
sedation in younger children, it is not routinely per-
formed in the pediatric rheumatology outpatient clinic.
Indocyanin green (ICG)-enhanced fluorescence optical
imaging (FOI) is a novel technology utilizing near-
infrared light to visualize altered microcirculation (e.g.,
neoangiogenesis, hyperperfusion, and capillary leakage)
in inflamed joints of the hands and wrists [20, 21].
Advantages of the method are the possibility of examin-
ing all joints of both hands (30 joints) together in a rela-
tively short time period (6 minutes), its standardized
setting, and the lack of ionizing radiation. However, the
application of an intravenous (IV) contrast agent (ICG)
might be disadvantageous, although possible side effects
are rarely seen.
Comprehensive validation studies on adult patients
with different arthritis have shown good agreement of
FOI with GSUS, PDUS, and MRI as well as variable sen-
sitivity and specificity dependent on FOI phase and joint,
by comparison [22–24]. These results cannot be simply
transferred to children and adolescents as the altered
vascularity of the juvenile cartilage and growth-related
changes might affect the imaging. There are few data
regarding its use in pediatric patients, yet first examina-
tions of children by FOI were promising and the
examination was well tolerated [25–27].
Our study was designed to determine the association and
agreement of FOI with US (GSUS, PDUS) findings and
physician assessment of clinical arthritic severity in joints of
symptomatic children, as well as to estimate the predictive
power of FOI to distinguish between inflammatory juvenile
rheumatic diseases and non-inflammatory arthralgia.
Methods
A total of 76 patients from three pediatric rheumatology
centers in Berlin, Germany were recruited for this obser-
vational study. The patients were consecutively included.
Inclusion criteria were joint pain (due to present JIA or
without known reason), age of 6–18 years, and agree-
ment of patient and parents. Exclusion criteria were al-
lergy against ICG or iodine, hyperthyroidism, pregnancy,
breast feeding, other known severe diseases, and chronic
or active infection of the hands.
The patients were categorized into three groups: group
I included 29 JIA patients with clinically relevant active
arthritis in the hand region at the time of examination (as
determined by pediatric rheumatologist); group II in-
cluded 23 patients with arthralgia (e.g., caused by hyper-
mobility syndrome, juvenile fibromyalgia, or other
arthralgia without inflammatory character); and group
III consisted of 53 JIA patients regardless of disease ac-
tivity and affection of the hand region at the time of
examination, and included all patients from group I. All
JIA patients included fulfilled the ILAR criteria [10]. In
patients with new onset of symptoms and/or uncertain
diagnosis at the time of examination, the diagnoses were
reconfirmed approximately 1 year later.
The study was performed in compliance with the Dec-
laration of Helsinki. The study protocol was approved by
the local ethics committee of the Charité University
Medicine Berlin, Germany (No. EA2/126/12). Written
informed consent was obtained from all participants.
Clinical and laboratory examinations
For each patient, a detailed CE was performed in all 71
joints. Joints were defined as clinically active by the pres-
ence of either joint swelling or tenderness and limited
range of motion. The assessment included a physician’s
global disease activity score by a 21-point numerical rat-
ing scale (NRS), patient’s/parent’s global assessment of
overall well-being by the same 21-point NRS, and an as-
sessment of the patient’s functional capacity by the
Childhood Health Assessment Questionnaire (CHAQ)
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score [28]. The clinical Juvenile Arthritis Disease Activ-
ity Score (cJADAS10, range 0–30), which counts any in-
volved joint to a maximum of 10 joints, was calculated
for JIA patients [29]. The erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) were determined for
65 and 71 patients respectively as part of their routine
examinations.
Musculoskeletal ultrasonography
Ultrasonographic examination of both hands was per-
formed in a neutral position by gray-scale (GSUS) and
power Doppler (PDUS) ultrasound with the following
two machines and settings: Mylab Twice (Esaote, Ge-
nova), GSUS 16-MHz frequency, linear probe and PDUS
9.1-MHz frequency, 750-Hz pulse repetition frequency
(PRF); and Philips HD15, GSUS 12-MHz frequency, lin-
ear probe and PDUS 5.5-MHz frequency, 600-Hz PRF.
The wrist, the interphalangeal joint of the thumb (IP),
and the metacarpophalangeal (MCP I–V), proximal (PIP
II–V), and distal interphalangeal (DIP II-V) joints were ex-
amined and scored semiquantitatively for presence of syn-
ovial thickening or joint effusion (combined as synovitis)
in GSUS (0 = absent, 1 =mild, 2 =moderate, 3 =marked)
and hyperperfusion in PDUS (0 = absent, 1 = presence of
up to three single color signals or one confluent signal in-
dicating hyperperfusion, 2 = perfusion signals in less than
half of the synovial/joint area, 3 = perfusion signal exceed-
ing half or more than half of the joint) [11].
GSUS and PDUS were analyzed blinded to the clinical
characteristics of the patient. For evaluation of interrea-
der agreement between the two pediatric centers con-
ducting sonographic examinations, a random sample
survey of 11 static GSUS and PDUS images was taken
from patients from center 1 and scored independently
by the center 2 pediatric rheumatologist.
Fluorescence optical imaging
FOI was performed in each patient with the Xiralite® X4
system (Mivenion, Berlin, Germany) following a stan-
dardized procedure [22]. Standard examination time was
6 minutes, recording one image per second and hence
adding up to a sequence of 360 images. A bolus of ICG
with a dose of 0.1 mg/kg body weight was injected as an
IV dye 10 seconds after the beginning of image acquisi-
tion. For interpretation, both film modus and an auto-
matically generated composite image (Prima Vista Mode
(PVM)) were considered. Evaluation was carried out ac-
cording to Werner et al. [22, 23], who defined three
phases of the film modus (P1, P2, P3) based on signal in-
tensity in the fingertips. P1 describes the time between
starting the examination and presentation of increased
signal intensities in the fingertips, P2 is defined as the
phase with persisting high signal intensities in the finger-
tips, and P3 begins with the absence of signal intensity
in the fingertips and lasts until the end of examination
(see Fig. 1). Each joint was scored semiquantitatively by
color intensity, size, and shape of enhancement from
grades 0 to 3 (0 = no signal enhancement, 1 = low signal
enhancement (≤25% of affected joint area), 2 =moderate
signal enhancement (>25 to ≤ 50% of affected joint area),
3 = strong signal (≥50% of affected joint area)). For each
patient the fluorescence optical imaging activity score
(FOIAS) was calculated as a sum score over all joints.
All FOI findings were analyzed in consensus by two
readers who were blinded to the clinical characteristics
of the patient (A-MG, MCB).
Statistical analyses
Data management and statistical analysis were
performed using SAS 9.3 (SAS Institute, Cary, NC,
USA). Statistical analyses were performed on the patient
and individual joint levels. The predictive value for
discrimination between patients with inflammatory and
non-inflammatory joint diseases by CE, GSUS, PDUS,
and FOI was evaluated by calculating the area under
receiver operating characteristics curve (AUC). The cor-
relation of CE, GSUS, PDUS, and FOI scores was
estimated by the standardized regression coefficient
from univariable linear regression analyses. The stan-
dardized regression coefficient is reported as a measure
Fig. 1 FOI findings in a patient with arthralgia (group II) without signs of inflammation. P1 describes the period between starting the examination and
increased signal intensities in the fingertips, the time point of increased signal intensity in the fingertips is analyzed for evaluation. P2 is defined as the
phase with persisting high signal intensities in the fingertips, the time point of a red-colored signal in the fingertips is analyzed for evaluation. P3
begins with the absence of signal intensity in the fingertips, and the time point of a missing (no) signal in the fingertips is analyzed for evaluation. PVM
automatically generated Prima Vista Mode, P1–P3 phases 1–3
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of association and can be interpreted as the correlation.
A robust variance estimator was used to account for the
possible correlation of CE, GSUS, PDUS, FOI, and CE
within the study sites [30]. A sum score of the gradings
across the 30 hand joints of a patient was considered for
the analyses on the patient level. Likewise, the associ-
ation of the different methods was analyzed on the joint
level. Agreement rates were determined at the individual
joint level taking into consideration all evaluated joints.
In each imaging method, a joint was considered to be af-
fected if its grading was greater than or equal to one
(grade ≥ 1) and otherwise to be unaffected (grade 0, nor-
mal). CE, GSUS, and PDUS were used as reference
methods for determining the absolute agreement, sensi-
tivity, and specificity between various pairs of modalities.
In order to investigate possible growth-related changes
of FOI during the pubertal growth spurt (i.e., increased
vascularization leading to more positive FOI results), we
further divided groups I and II into patients aged < 13
and patients aged ≥ 13 and analyzed the respective distri-
bution of the FOI sum scores. Besides, interreader agree-





Twenty-nine JIA patients with clinically relevant active
arthritis in the hand region were included in this group.
Mean age at examination was 13.7 years (standard devi-
ation (SD) = 3.3, median = 14.0); mean number of joints
with clinically active arthritis in the hand region was 7.1
(SD = 5.2). Clinical parameters at study enrolment are
presented in detail in Table 1.
Comparison of CE, US, and FOI
FOI findings were compared with US findings (Figs. 2 and 3)
and clinical findings in 870 wrist and finger joints.
Prevalence of joints with pathological findings was 206
(24%), 281 (32%), 118 (14%), and 395 (45%) by CE,
GSUS, PDUS, and FOI, respectively. Most frequently af-
fected joints in each method were the wrists as well as
PIP joints. In FOI, the largest number of increased signal
intensities was found in P2 (34% of joints). The number
of joints with grading ≥ 2 was 87 (10%) in GSUS, 27 (3%)
in PDUS, and 233 (26.8%) in FOI.
The age-related distribution of FOI scores showed no
relevant differences between patients aged < 13 and pa-
tients aged ≥ 13 years (Fig. 4).
Sensitivity and specificity
Of the 206 joints rated as clinically active, 57.3%/32.5%
were also positive by GSUS/PDUS and 75.2% by FOI. Of
the 664 non-inflamed joints by CE, 75.5%/92.3% was
negative in GSUS/PDUS and 63.9% was negative in FOI.
With CE as reference, FOI sensitivity was highest in P2
(62.6%) and specificity was highest in P3 (93.1%).
Taking GSUS as reference, CE had a sensitivity of
42.0% and a specificity of 85.1% and FOI had a sensitiv-
ity of 67.3% and a specificity of 65.0%. With PDUS as
reference, CE had a sensitivity of 56.8% and a specificity
of 81.5% while FOI had a sensitivity of 72.0% and a spe-
cificity of 58.8%. Specificity of FOI compared to US was
high in PVM and P3 (GSUS 86.9% and 94.3%; PDUS
84.8% and 91.7%). However, corresponding sensitivities
were low (GSUS 28.1% and 18.6%; PDUS 35.6% and
20.3%). Sensitivity of FOI was highest in P1 (GSUS
51.8%; PDUS 59.8%) (Table 2).
Agreement rates
Agreement of CE and US (GSUS and/or PDUS) was
71.6%. Agreement of CE and FOI ranged from 71.8 to
78.2% depending on the individual phases of FOI, agree-
ment of GSUS and FOI ranged from 66.7 to 70.5%, and
agreement of PDUS and FOI ranged from 67.9 to 81.9%.
Highest agreement was found for P3 where mostly nega-
tive results were present, the lowest was found for P2
(Table 2). Lack of accordance was primarily due to a
higher proportion of positive findings by FOI; in 16.8%
of joints only FOI was rated positive. US and FOI con-
sistently detected abnormal findings in 47.6% of clinic-
ally active joints and in 14.2% of clinically inactive joints.
Group II
Study population
Twenty-three patients with arthralgia without any known
inflammatory rheumatic disease were included in this
group. None showed signs of clinical inflammation in any
joint region. Mean age at examination was 13.8 years (SD
= 2.4, median = 14.9); mean number of joints with arthral-
gia in the hand region was 5.2 (SD = 7.9). Clinical parame-
ters are presented in detail in Table 1.
Comparison of CE, US, and FOI
Figure 1 shows a typical FOI image sequence of a patient
with arthralgia but without any increased signal intensity
as a sign of inflammation in any phase.
Of the 690 wrists and finger joints evaluated, none had
clinical signs of arthritis. However, 17 patients showed
abnormalities in GSUS and/or PDUS suggestive of in-
flammatory activity in 96 joints (14%) (GSUS 94 joints,
PDUS 13 joints), and 21 patients showed increased sig-
nal intensities in FOI in 172 joints (25%). The number of
joints with grading ≥ 2 was 17 (2.4%) in GSUS, one
(0.1%) in PDUS, and 53 (7.7%) in FOI. In FOI, P2
showed most increased signal intensities (16.8%),
whereas P3 showed least signals and thus was most
specific (98.2%). In US, most positive results were found
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Table 1 Demographic and clinical data of the study population
Group I: JIA patients with clinically active
arthritis in the hand region
Group II: non-inflammatory
joint diseases
Group III: all JIA
patients
(n = 29) (n = 23) (n = 53)
n % n % n %
Gender
Female 23 79 19 83 45 85
Male 6 21 4 17 8 15
Age (years), mean (SD); median 13.7 (3.3); 14.0 13.8 (2.4); 14.9 13.7 (3.3); 14.1
Disease duration (years), mean (SD); median 3.3 (4.0); 1.6 1.7 (1.8); 1.1 3.7 (4.1); 2.1
Diagnosis
Juvenile idiopathic arthritis 29 100.0 n.a. n.a. 53 100.0
Systemic arthritis 0 0.0 n.a. n.a. 1 2
Oligoarthritis, persistent 0 0.0 n.a. n.a. 6 11
Oligoarthritis, extended 0 0.0 n.a. n.a. 1 2
Polyarthritis, seronegative 19 66 n.a. n.a. 28 53
Polyarthritis, seropositive 5 17 n.a. n.a. 7 13
Enthesitis-related arthritis 2 7 n.a. n.a. 6 11
Psoriatic arthritis 2 7 n.a. n.a. 3 6
Other arthritis 1 3 n.a. n.a. 1 2
Arthralgia n.a. n.a. 23 100 n.a. n.a.
Physician’s global assessment (NRS 0–10)
Mean (SD) 3.4 (1.9) n.a. 2.4 (1.9)
Inactive disease (NRS < 1) 0 0.0 n.a n.a. 9 17
Therapy
Nonsteroidal anti-inflammatory drugs 20 69 10 43.5 31 59
Systemic glucocorticoids, low dose 5 17 0 0.0 6 11
Systemic glucocorticoids, high dose 3 10 0 0.0 3 6
Disease-modifying antirheumatic drugs 19 65 0 0.0 32 60
Methotrexate 15 52 0 0.0 23 43
Sulfasalazine 2 7 0 0.0 3 6
Leflunomide 1 3 0 0.0 1 2
Etanercept 4 14 0 0.0 6 11
Adalimumab 0 0.0 0 0.0 3 6
Abatacept 1 3 0 0.0 1 2
Tocilizumab 2 7 0 0.0 2 4
Canakinumab 1 3 0 0.0 1 2
ESR (mm/h), mean (SD); n 17.0 (19.2); 24 9.5 (6.5); 21 14.8 (16.1); 44
CRP (mg/dl), mean (SD); n 0.4 (0.5); 28 0.1 (0.1); 23 0.3 (0.5); 48
cJADAS-10
Mean (SD) 13.3 (4.8) n.a 9.5 (5.9)
Inactive disease (cJADAS-10 ≤ 1) 0 0.0 n.a. 3 6
CHAQ
Mean (SD) 0.7 (0.6) 0.5 (0.6) 0.5 (0.6)
No functional disability (CHAQ = 0) 7 24 8 27 16 30
Patient’s Global Assessment (NRS 0–10), mean (SD) 2.6 (2.2) 3.9 (3.4) 2.6 (2.2)
JIA juvenile idiopathic arthritis, SD standard deviation, n.a. not applicable, NRS numerical rating scale, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, cJADAS clinical Juvenile Arthritis Disease Activity Score, CHAQ Childhood Health Assessment Questionnaire
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in the wrists and MCP joints, and in FOI most positive
results were found in the wrists and PIP joints.
Again, the age-related distribution of FOI scores showed
no relevant differences between patients aged < 13 and
patients aged ≥ 13 years (Fig. 4).
Sensitivity, specificity, and agreement rates of US and FOI
Agreement of US and FOI was high, given the fact that
most results were expected to be negative. With both
GSUS and PDUS as reference, FOI had specificity up to
98.6% (in P3, respectively). However, overall sensitivity
was relatively low (GSUS 39.4%; PDUS 61.5%). In 5.5% of
joints both imaging methods showed positive findings.
Groups I and II: predictive value of FOI, GSUS/PDUS, and
diagnosis and their correlations
The predictive value for discrimination between inflam-
matory and non-inflammatory rheumatic diseases was cal-
culated. The area under the curve (95% CI) was 0.85
(0.75–0.95) for PDUS, 0.80 (0.68–0.92) for GSUS, and
0.79 (0.67–0.91) for any FOI phase (P2 = 0.77 (0.64–0.89)).
On the patient level, correlation of US with joints with
clinically active arthritis was strong (GSUS, β = 0.63 (p <
0.001); PDUS, β = 0.69 (p < 0.001)), whereas correlation
of FOI with clinically active arthritis was moderate (β =
0.32–0.54 (p < 0.001)). Correlation of FOI with US was
moderate. P1 was found to correlate most strongly with
GSUS (β = 0.50 (p < 0.001) and P2 with PDUS (β = 0.51
(p < 0.001)) (Table 3). On the joint level, correlation of
US with clinically active joints was moderate (GSUS, β =
0.37 (p < 0.001); PDUS, β = 0.35 (p > 0.001)), as well as
correlation of FOI with clinically active joints (up to β =
0.40 (p < 0.001) for any FOI phase). Correlation of FOI
with GSUS was weak to moderate (up to β = 0.35 (p <
0.001) in P2); there was no correlation between FOI and
PDUS on the joint level (Table 4).
Group III
Study population
This group consisted of 53 JIA patients with variable
current disease activity in the hand region, and included
all 29 patients of group 1. Mean age at examination was
13.7 years (SD = 3.3, median = 14.1); mean number of
joints with arthritis in the hand region was 4.1 (SD = 5.1).
Clinical parameters are presented in detail in Table 1.
Findings in CE, US, and FOI
Of 1590 joints evaluated, 218 (13.7%) were classified as
clinically active. US was positive in 26% and FOI in
41.3% of all joints examined.
Correlations of FOI and US with clinical and functional
parameter of disease activity
Synovitis scores and FOIAS were compared with the
cJADAS10, physician’s global assessment of disease
activity, functional disability scores (CHAQ), and labora-
tory parameters (ESR, CRP) (Table 5). Correlation
between GSUS/PDUS and cJADAS10 was found to be
Fig. 2 FOI findings in a 17-year-old patient with clinically active seronegative polyarthritis (group I). Increased signal intensities as a sign of active
inflammation (synovitis) can be seen in both hands especially in P1 as follows: high signal intensities (FOIAS grade 3) in MCP 4 + 5, PIP 3 + 5, and
DIP 3 of the right hand; moderate signal intensities (FOIAS grade 2) in MCP 2, PIP 2 + 4, and DIP 2 of the right hand; and FOIAS grade 1 in IP of
the right hand and DIP 2 + 3 and PIP 2 + 3 + 5 of the left hand. PVM Prima Vista Mode, P1–P3 FOI phases 1–3
Fig. 3 Gray-scale (GSUS) and power Doppler (PDUS) ultrasonography findings in a 13-year-old patient with clinically active seronegative polyarthritis
(group I). a GSUS synovitis grade 3 and PDUS activity grade 2 as a sign of active synovitis in the right wrist (radiocarpal and intercarpal joint). b GSUS
synovitis grade 2 and PDUS activity grade 3 (≥50% of the intraarticular area) as a sign of active synovitis in the right PIP3 joint from dorsal. PIP proximal
interphalangeal joint
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relevant (β = 0.62 (p < 0.001)/β = 0.66 (p < 0.001)), as well
as correlation with physician’s global assessment of disease
activity (β = 0.51 (p < 0.001)/β = 0.55 (p < 0.001)). There
was a weak correlation between GSUS/PDUS and CHAQ
(β = 0.32 (p = 0.018)/β = 0.36 (p = 0.008)) and no correl-
ation with the patient-reported outcome measurements
pain and fatigue. GSUS/PDUS and inflammatory blood
parameters did not show any correlation.
Correlation between FOIAS and cJADAS10 was moderate
(P2, β= 0.42 (p= 0.002)), as well as correlations with
physician’s global assessment of disease activity (P2, β= 0.38
(p= 0.005)). FOI PVM correlated moderately with CRP level
(β= 0.48 (p= 0.0001)). There was no correlation between
FOIAS and CHAQ or between FOIAS and patient-reported
outcome measurements of pain and fatigue.
Interreader agreement for ultrasonography
Interreader agreement was investigated in 11 static GSUS
and PDUS images between two blinded independent
raters. Interreader agreement was found to be good for
GSUS (agreement in 93% of joints, κ = 0.76) and substan-
tial for PDUS (agreement in 100% of joints, κ = 1.00),
when considering the number of joints with any positive
signal. The agreement rate for the grading was slightly
lower for GSUS (agreement in 60% of joints, κ = 0.61) and
PDUS (agreement in 66% of joints, κ = 0.70). The highest
proportion of disagreement was found between grading 1
and 2 (GSUS, 20% of joints; PDUS, 26% of joints).
Safety
In all subjects, the procedure was well tolerated. One pa-
tient presented circulatory problems due to peripheral
Fig. 4 Comparison of cumulative probability plot of fluorescence optical
imaging scores (FOIAS) for patients aged < 13 years and patients aged≥
13 years in group I (JIA patients with clinically active arthritis in hand
region) and group II (patients with non-inflammatory joint diseases)
Table 2 Group I and II: agreement (%), sensitivity (%), and specificity (%) of FOI, CE, GSUS, and PDUS vs CE, GSUS, and PDUS as
standards of reference
CE GSUS PDUS
Agreement Sensitivity Specificity Agreement Sensitivity Specificity Agreement Sensitivity Specificity
Group I: JIA with clinically active arthritis in the hand region
FOI any phase 66.6 75.2 63.9 65.7 67.3 65.0 60.6 72.0 58.8
PVM 78.2 41.7 89.5 67.9 28.1 86.9 78.2 35.6 84.8
P1 72.3 56.3 77.2 70.5 51.8 79.7 72.1 59.8 74.0
P2 71.8 62.6 74.7 66.7 51.2 74.0 67.9 57.6 69.5
P3 75.3 19.4 93.1 69.5 18.6 94.3 81.9 20.3 91.7
CE – – – 71.1 42.0 85.1 78.2 56.8 81.5
GSUS 71.1 57.3 75.5 – – – 80.3 96.6 77.8
PDUS 78.2 32.5 92.3 80.3 40.6 99.3 – – –
Group II: non-inflammatory joint diseases
FOI any phase 75.0 0.0 75.0 72.1 39.4 77.3 75.5 61.5 75.7
PVM 93.3 0.0 93.3 84.6 18.1 95.1 92.3 23.1 93.6
P1 88.0 0.0 88.0 80.1 21.3 89.4 86.6 15.4 88.0
P2 83.2 0.0 83.2 77.1 27.7 84.9 83.3 53.8 83.9
P3 98.2 0.0 98.2 86.0 4.5 98.6 97.1 23.1 98.6
CE – – – 86.4 0.0 100.0 98.1 0.0 100.0
GSUS 86.4 0.0 86.4 – – – 87.7 84.6 87.7
PDUS 98.1 0.0 98.1 87.7 11.7 99.7 – – –
FOI fluorescence optical imaging, CE clinical examination (joints with clinically active arthritis), GSUS ultrasonography in gray-scale mode, PDUS ultrasonography in
power Doppler mode, JIA juvenile idiopathic arthritis, PVM Prima Vista Mode, P1–P3 FOI phases 1–3
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IV insertion before the fluorescent compound was
applied. The FOI examination could be performed after
recovery. No adverse events were observed.
Discussion
ICG-enhanced FOI with the Xiralite® system is a novel
imaging technique that has been shown to visualize in-
flammation in arthritis of wrist and finger joints and has
been evaluated in various validation studies in adult
rheumatology [22–24, 31, 32]. The aim of this study was
to acquire data regarding the use of FOI in children and
adolescents with joint diseases by comparing it to find-
ings in both sonographic and CE.
Patients with juvenile idiopathic arthritis
Consistent with previous studies in adults [22–24], FOI
showed a higher rate of positive findings than the other
compared modalities. Most signals were found in P2,
which was also the most sensitive phase compared to
CE (62.6%). This supports the hypothesis that it might
be the most valuable phase for detecting subclinical ac-
tivity [22–24]. However, there is a need for further
evaluation to prove this.
Agreement of FOI and CE was comparable to agree-
ment of GSUS/PDUS and CE, whereas FOI overall sen-
sitivity for detecting clinically active arthritis was higher
than GSUS/PDUS sensitivity (75.2% vs 57.3%/32.5%).
Agreement of FOI and US was good, especially agree-
ment with PDUS (up to 81.9%), which reflects the fact
that both FOI and PDUS display acute inflammatory
changes rather than chronic changes. Sensitivity of FOI
compared to US was moderate. The highest values were
reached if increased signal intensities in any phase were
considered (GSUS 67.3%, PDUS 72.0%). Analyzing the
phases separately, highest sensitivity was found for FOI
P1 compared to hyperperfusion in PDUS in JIA patients
with clinically active arthritis (59.8%) with corresponding
high specificity (74.0%). This supports the theory by
Werner et al. [22] that P1 reflects high synovial
vascularization and thus correlates best with disease
activity [33]. However, these results distinguish from
results of previous studies comparing FOI to US which
found P2 to be the most sensitive phase [22–24].
In accordance with adult studies, highest specificity com-
pared to both GSUS and PDUS was found for P3 (94.3%
and 91.7%). This was the phase showing least signal intensity
increase; presumably it reflects increased capillary permeabil-
ity with abnormal persistency of ICG and is therefore mostly
found positive in osteoarthritis [22, 23, 34].
Differences in the characteristics of the FOI phases
compared to previous studies might result from the higher
variation of ICG distribution patterns we observed in chil-
dren and adolescents compared to adults. Defining the
phases according to the standardized protocol was diffi-
cult in several cases, where the ICG distribution deviated
from the known characteristic flow behavior. This is pos-
sibly due to growth-related vascular changes and might
have had an influence on sensitivity and agreement rates
of the individual phases. Therefore, the current standard
of interpretation in adult rheumatology by Werner et al.
[22, 23]—in particular the definitions of the phases—might
have to be reevaluated for pediatric rheumatology. This
could also be concluded by means of the moderate corre-
lations of US and FOI scores on the joint and patient levels
(Tables 3 and 4). We found no relevant differences in the
distribution of FOIAS scores between patients aged <
13 years and patients aged ≥ 13 years (see Fig. 4). Never-
theless, further age-related examinations are needed for
evaluation of growth-related changes in FOI.
Both FOI and US detected a high number of positive
results in clinically asymptomatic joints of JIA patients.
In adult rheumatology, it is known that residual synovitis
in patients with rheumatoid arthritis in clinical remis-
sion is frequent and predicts the risk of relapse and on-
going structural joint damage [35]. Even though there
are follow-up reports suggesting that subclinical arthritis
detected by US also predicts development of clinical
Table 3 Group I and II: correlation of FOI, GSUS/PDUS, and CE




FOI any phase 0.54 (<0.001) 0.48 (<0.001) 0.43 (0.001)
PVM 0.45 (0.001) 0.38 (0.006) 0.43 (0.001)
P1 0.52 (<0.001) 0.50 (<0.001) 0.38 (0.006)
P2 0.54 (<0.001) 0.45 (0.001) 0.51 (<0.001)
P3 0.32 (0.020) 0.46 (0.001) 0.43 (0.002)
GSUS 0.63 (<0.001) – –
PDUS 0.69 (<0.001) – –
FOI fluorescence optical imaging, CE clinical examination (joints with clinically
active arthritis), GSUS ultrasonography in gray-scale mode, PDUS ultrasonography
in power Doppler mode, PVM Prima Vista Mode, P1–P3 FOI phases 1–3
Table 4 Group I and II: correlation of FOI, GSUS/PDUS, and CE
on the joint level; standardized β (p value)
Joints with active arthritis GSUS PDUS
FOI any phase 0.40 (<0.001) 0.35 (<0.001) 0.29 (0.001)
PVM 0.35 (0.001) 0.23 (0.006) 0.20 (0.001)
P1 0.36 (<0.001) 0.35 (<0.001) 0.27 (0.006)
P2 0.36 (<0.001) 0.30 (0.001) 0.25 (<0.001)
P3 0.23 (0.020) 0.23 (0.001) 0.19 (0.002)
GSUS 0.37 (<0.001) – –
PDUS 0.35 (<0.001) – –
FOI fluorescence optical imaging, CE clinical examination (joints with clinically
active arthritis), GSUS ultrasonography in gray-scale mode, PDUS ultrasonography
in power Doppler mode, PVM Prima Vista Mode, P1–P3 FOI phases 1–3
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arthritis in JIA patients [36], direct evidence from compar-
ing US to histopathological findings—as has been pro-
vided for adults—has not been (and most likely will not
be) tested for children. Pre/post comparisons of adult pa-
tients with inflammatory arthritis in clinical remission
suggested that positive signals in FOI in clinically asymp-
tomatic joints may also predict a relapse after premature
withdrawal of treatment [37]. A recent study found FOI to
be particularly sensitive in detecting clinically silent in-
flammation in joints that were positive by US [31].
In our study, agreement of US and FOI in clinically
inactive joints that presented abnormalities in imaging
was relatively low (up to 25.4%), showing that such pre-
clinical/subclinical findings in children and adolescents
have to be interpreted with caution. After all, validity of
US in pediatric rheumatology has still not been fully
established and preliminary standardized definitions of
synovitis in US were established only recently [38]. Add-
itionally, it is known that there is a wide range of
growth-related variations in joints of children and ado-
lescents that can be seen on imaging. In MRI studies of
patients with JIA, changes in bone shape, signal inten-
sity, and the amount of joint fluid were found that were
partly unrelated to disease activity [39]. Moreover, bony
depressions resembling erosions are frequently seen on
MRI of healthy children [19]. Therefore, the clinical im-
portance of such findings in both MRI and FOI remains
to be determined and it is unclear whether FOI findings
in asymptomatic joints of JIA patients demonstrate sub-
clinical inflammation and thus predict development of
clinically apparent arthritis. In the future, follow-up
studies could help in evaluating their significance.
Patients with arthralgia without any known inflammatory
rheumatic disease
This group served as a control group, because none of the
patients presented clinical signs of an inflammatory joint
disease. Previous examinations of healthy controls and in-
dividuals with arthralgia without any sign of inflammatory
rheumatic disease showed a low rate of positive findings
in FOI (0–5%) [22, 23]. However, a vast majority of 91% of
this group had increased signal enhancements in at least
one joint and phase. Also, 74% of the patients showed ab-
normalities in US suggestive of synovitis.
Remarkably, there was only moderate agreement be-
tween the positive results detected by US and FOI, sug-
gesting that the mechanisms causing such findings differ
between the two techniques. This is most likely due to
the fact that FOI is based on different physical principles
than US, such as light optics and microangiography.
Thus, it should be considered a complementary rather
than a competitive imaging method.
The high number of positive signals in both US and
FOI resulted from many joints being scored grade 1. Ex-
cluding those joints greatly minimized positive results
and led to high specificities (FOI 94.5–99.2%, US 97.4%).
For clinical use, this could mean that FOI tends to over-
estimate findings and that discreet findings with scores
< 2, especially in P2, should be interpreted with caution
in children with suspected inflammatory rheumatic
diseases, as they might not be a sign of active arthritis
but of mechanical stress or blood flow alterations. As dis-
cussed before, this possibility should also be considered
for patients with inflammatory diseases with positive
signals in clinically inactive joints. However, any finding in
P3 should be taken seriously, as this highly specific phase
might reflect the presence of inflammation.
Most positive results in both US and FOI in patients
with non-inflammatory diseases were found in the
wrists. Interestingly, these results are compatible with
observations in a healthy control group whose wrists
were examined by MRI, where a high prevalence of in-
creased volumes of joint fluid, signal changes similar to
bone marrow edema, and bony depressions resembling
erosions were found [19]. Both MRI and FOI findings
might reflect mechanical stress through the high use of
this part of the hand during daily activity.
The predictive value for discrimination between active
inflammatory and non-inflammatory conditions was cal-
culated. We found it to be comparably high for both
GSUS/PDUS and FOI (0.80/0.85 and 0.79) with slight
advantages for US, showing that they are equally valid
methods for differential diagnosis in children and
adolescents with unclear joint pain.
Limitations
Our study has some limitations. Specific limitations of
the technology include the lack of visualization of
Table 5 Group III: correlation of FOI, GSUS, and PDUS with clinical parameters; β (p value)
GSUS PDUS FOI any phase PVM P1 P2 P3
Physician’s assessment 0.51 (<0.001) 0.55 (<0.001) 0.37 (0.007) 0.37 (0.006) 0.36 (0.008) 0.38 (0.005) 0.29 (0.034)
Number of joints with arthritis 0.59 (<0.001) 0.63 (<0.001) 0.39 (0.004) 0.36 (0.008) 0.36 (0.008) 0.46 (<0.001) 0.30 (0.028)
cJADAS-10 0.62 (<0.001) 0.66 (<0.001) 0.36 (0.008) 0.36 (0.008) 0.34 (0.013) 0.42 (0.002) 0.37 (0.007)
CHAQ score 0.32 (0.019) 0.36 (0.008) 0.10 (0.471) 0.22 (0.106) 0.12 (0.388) 0.21 (0.127) 0.17 (0.238)
FOI fluorescence optical imaging, GSUS ultrasonography in gray-scale mode, PDUS ultrasonography in power Doppler mode, PVM Prima Vista Mode, P1–P3 FOI
phases 1–3, cJADAS clinical Juvenile Arthritis Disease Activity Score, CHAQ Childhood Health Assessment Questionnaire
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anatomic structures as well as the limited ability to assess
palmar inflammation due to overlying structures reducing
the depth of light penetration, most notably in the area of
MCP joints. Also, FOI is currently available for examin-
ation of hands and wrists only, whereas the most common
category of JIA—oligoarthritis—is often manifest in the
knee or ankle joint. Therefore, the method might be more
valuable for polyarticular-course JIA. Furthermore, it is
limited to older children as the method’s fixed setup re-
quires the patient’s capability to keep still for 6 minutes as
well as a minimum arm’s length. The youngest patient ex-
amined in our study was 6.5 years old.
FOI demonstrates any inflammation of the hand region
including scratches or psoriatic plaques, which can result in
signal enhancement similar to synovitis. Even though expe-
rienced readers are able to identify signals caused by such
skin lesions, any clinical findings should be documented in
order to be considered in image interpretation [40].
FOI is a procedure that includes an IV injection with po-
tential side effects, like circulatory problems and allergic re-
actions. In our study, FOI examination was tolerated well,
with one report of circulatory problems due to peripheral
IV insertion before the fluorescent compound was applied.
The study population was rather inhomogeneous in-
cluding several patients with unclear clinical findings at
the time of examination. In hindsight, this limitation
could be reduced by verifying every patient’s diagnosis
approximately 1 year after the examination. Another
limitation was the use of two different US machines with
potential variance in resolution and display.
Ultimately, we were confronted with the problem that
there is no assured gold standard for detection of syno-
vitis in children, which is why sensitivities and specific-
ities should be regarded with reserve. Because of the fact
that MRI is an invasive technique and not a routine
procedure in pediatric rheumatology, we were not able
to include it as a reference method in our study.
Conclusions
ICG-enhanced FOI is a new imaging technique in
rheumatology. It detects and excludes inflammatory
changes in joints of children and adolescents in good
agreement with sonography and CE.
FOI had the highest rate of positive findings of all
methods and showed signal enhancements in a majority
of patients without known inflammatory rheumatic
diseases, which is why discreet findings should always be
put in a clinical context. Sonographic examination also
showed limitations, proving that despite its value in clin-
ical routine it cannot be regarded as an assured standard
of reference in pediatric rheumatology. After all, both
diagnostic methods need to be interpreted with caution
in the use of children in order not to overestimate their
findings. Diagnosis of patients with unclear clinical
findings remains challenging. However, FOI is a simple,
non-ionizing, and well-tolerated method that could serve
as an additional diagnostic tool in pediatric rheumatol-
ogy. In order to further evaluate the value of this
method, and particularly its subclinical findings, more
studies in pediatric rheumatology are needed.
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